FindTrial
Sign In

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02223416
Enrollment
Unknown
Registered
2014-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2015-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

female, volunteers

Brief summary

Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.

Interventions

DRUGRGB-10
DRUGTeriparatide

Sponsors

Gedeon Richter Plc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adult female subjects * 18-55 years of age (inclusive) * BMI must be between 18.5 and 27 kg/m2 (inclusive)

Design outcomes

Primary

MeasureTime frame
Area under the plasma concentration versus time curve (AUC)0-4 hours
Peak Plasma Concentration (Cmax)0-4 hours

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026